Summary: In order to relieve esophageal impaction, glucagon is frequently used. This study was a systematic and meta-analysis that evaluated the efficacy of glucagon for esophageal impactions. The studies that were included were  either retrospective, prospective observational, and randomized controlled trials. These studies had either a control group or placebo and must have been conducted on humans. Five  studies were selected and ages of the patients ranged from 5.1 to 59.5 years of age. The primary outcome that was evaluated was the success of glucagon as a treatment. 213 out of 706 patients in the glucagon group and 158  out of 479 patients in the control group experienced successful treatment with glucagon. There was no statistical difference between these two groups. The secondary outcome that was evaluated were adverse effects. Adverse events were identified in 24 patients in the glucagon group and 0 patients in the placebo group. All the studies were overall at low bias risk. This is one of the first large scale studies that examines the efficacy of glucagon. It concluded that glucagon is not an effective measure to relieve esophageal impaction. However, it does discuss how glucagon can be tried as a medical therapy. In order to relieve esophageal impaction  endoscopic intervention is required within 24 hours which causes glucagon to be considered in the meantime. Although the results suggest that glucagon does not significantly improve outcomes for esophageal impaction, more RCTs are required to better assess glucagons efficacy.